Canadian study tracks Real-World use of heart drug mavacamten
NCT ID NCT06549608
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviewed information from 683 adults with obstructive hypertrophic cardiomyopathy who took mavacamten through a support program in Canada. Researchers looked at patient characteristics and how long they stayed on the medication. The goal was to understand real-world use, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Paul's Hospital
Vancouver, British Columbia, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart scans may unlock hidden risks in minority communities
- Global registry aims to unlock clues for heart transplant success in adults born with heart defects
- Heart conditions in kids: study reveals impact on daily life and play
- Could a simple scan unlock better heart treatment?
- Gene hunt launched for kids with heart muscle disease
- Heart study reveals hidden link between blood vessels and muscle blockage